MRNA - Moderna BioNTech among healthcare laggards this week amid early Omicron data

As early lab results on the vaccine effectiveness against the Omicron variant started to emerge, COVID-19 vaccine stocks led by BioNTech (NASDAQ:BNTX) and Moderna (NASDAQ:MRNA) sank this week, dragging the NASDAQ Biotechnology Index (NASDAQ:IBB) for the second consecutive week. However, the healthcare stocks in the S&P 500 recorded the best weekly gain since early this year on the strength of healthcare providers and services. Yet, rising 3.8%, the overall index outperformed healthcare as the sector added ~3.2% over the week to become the fifth-best. Among stocks with more than $2B market capitalization and 100K average daily volume over the week, Bright Health Group (NYSE:BHG) rose the most with a ~29.5% gain after setting its 2022 guidance ahead of expectations. Before the guidance issuance, a newly announced plan for a $750M worth of capital raise propelled the shares of the health insurer in the post-market Monday. Rising ~25.4%, Sorrento Therapeutics (NASDAQ:SRNE) dominated news flow this

For further details see:

Moderna, BioNTech among healthcare laggards this week amid early Omicron data